ArticleCancer discovery2020
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Review
- MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy.Cancer science · 2026Review
- Article
- Article
- Review
- C6orf223 promotes colorectal cancer growth and metastasis by facilitating PRMT5-MEP50 multiprotein complex assembling.The Journal of clinical investigation · 2025Article
- Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment.bioRxiv : the preprint server for biology · 2025Article
- Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.American journal of hematology · 2025Review
- PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis.Blood advances · 2025Article
- PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy.Journal for immunotherapy of cancer · 2025Article
- Post-translational modifications of protein and lung cancer.Frontiers in oncology · 2025Review
- Alternative splicing in ovarian cancer.Cell communication and signaling : CCS · 2024Review
- Mechanism of Histone Arginine Methylation Dynamic Change in Cellular Stress.International journal of molecular sciences · 2024Article
- PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.Nature communications · 2024Article
- PRMT5-mediated homologous recombination repair is essential to maintain genomic integrity of neural progenitor cells.Cellular and molecular life sciences : CMLS · 2024Article
- Order-of-Mutation Effects on Cancer Progression: Models for Myeloproliferative Neoplasm.Bulletin of mathematical biology · 2024Article
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.Cancers · 2024Review
- PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies.Cancer research communications · 2023Article
- PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 3 institutions in 2 countries.
Friederike PastoreMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Neha BhagwatPrelude Therapeutics Inc., Wilmington, Delaware.
Alessandro PastoreMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Aliaksandra RadzisheuskayaCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Abdul KarzaiMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Aishwarya KrishnanMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Bing LiMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert L BowmanMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Wenbin XiaoMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0001-8586-8500
Aaron D VinyMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Anouar ZouakMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Young C ParkMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Keith B CordnerMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Stephanie BraunsteinMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Jesper L MaagCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-2578-8872
Alexander GregoPrelude Therapeutics Inc., Wilmington, Delaware.
Jaanvi MehtaPrelude Therapeutics Inc., Wilmington, Delaware.
Min WangPrelude Therapeutics Inc., Wilmington, Delaware.
Hong LinPrelude Therapeutics Inc., Wilmington, Delaware.
Benjamin H DurhamMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Raajit K RampalMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0002-0355-6368
Kristian HelinCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID https://orcid.org/0000-0003-1975-6097
Peggy ScherlePrelude Therapeutics Inc., Wilmington, Delaware.
Kris VaddiPrelude Therapeutics Inc., Wilmington, Delaware.
Ross L LevineMolecular Cancer Medicine Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. leviner@mskcc.org.
Memorial Sloan Kettering Cancer Center · USWilmington University · USUniversity of Copenhagen · DK
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0MRole of the Cohesin complex in normal and malignant hematopoiesisK08CA215317 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VINY, AARON D · 2018 to 2022
$1.3MCellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological MalignanciesK08CA218901 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DURHAM, BENJAMIN HEATH · 2018 to 2022
$1.0MGenomic profiling and development of murine models of transformation of MPNsK08CA188529 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RAMPAL, RAAJIT · 2014 to 2018
$891kInterrogating oncogene-dependency and mutation order in FLT3 mutant AMLK99CA248460 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOWMAN, ROBERT LYLE · 2020 to 2021
$297kNCI NIH HHS K08 CA188529NCI NIH HHS K08 CA215317NCI NIH HHS K08 CA218901NCI NIH HHS K99 CA248460NCI NIH HHS P01 CA108671NCI NIH HHS P30 CA008748
Abstract
We investigated the role of PRMT5 in myeloproliferative neoplasm (MPN) pathogenesis and aimed to elucidate key PRMT5 targets contributing to MPN maintenance. PRMT5 is overexpressed in primary MPN cells, and PRMT5 inhibition potently reduced MPN cell proliferation
Indexed as
E2F1 Transcription FactorGene Regulatory NetworksHumansJanus Kinase 2MethylationMutationProtein-Arginine N-MethyltransferasesE2F1 protein, humanE2F1 Transcription FactorJAK2 protein, humanJanus Kinase 2PRMT5 protein, humanProtein-Arginine N-Methyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.